<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01322100</url>
  </required_header>
  <id_info>
    <org_study_id>HJ 1020</org_study_id>
    <nct_id>NCT01322100</nct_id>
  </id_info>
  <brief_title>Electrochemotherapy as a Palliative Treatment for Brain Metastases</brief_title>
  <official_title>Electrochemotherapy as a Palliative Treatment for Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Copenhagen University Hospital at Herlev</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Glostrup University Hospital, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Copenhagen University Hospital at Herlev</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Because electrochemotherapy is a quick and effective treatment for cutaneous metastases, a
      novel electrode device has been developed for treatment in soft tissue such as the brain. Up
      to 18 patients will be treated in this phase I dose-escalating study of electrochemotherapy
      for brain metastases. Primary endpoint of the clinical trial is safety and secondary endpoint
      is efficacy. One brain metastasis is treated once-only with the electrode device guided
      stereotactically through a burr hole using CT monitoring. The patient will be fully
      anesthetized during the treatment procedure. Patients are followed up for 6 months with
      regard to neurological function, Barthel Index, steroid use and adverse effects registration
      (CTCAE). Tumor response will be evaluated by Magnetic Resonance imaging (MRI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Electrochemotherapy is a cancer treatment modality comprising of a combination of electrical
      pulses delivered by electrodes and chemotherapy supplied either intravenously or
      intratumorally. It is a quick and effective treatment for cutaneous metastases &lt; 3 cm with a
      complete response rate of 73 % after once-only treatment. The available electrode devices
      have so far only been applicable for cutaneous tumors. An electrode has now been developed in
      collaboration with a medico-technical company. An increasing number of cancer patients suffer
      from metastases to the brain due to e.g. better control of the systemic peripheral cancer
      disease. The prognosis for patients with brain metastases remains poor and research into new
      treatments are needed in this field.

      Up to 18 patients will be treated in a dose-escalating study of electrochemotherapy for brain
      metastases. Primary endpoint of the clinical trial is safety and secondary endpoint is
      efficacy. One brain metastasis is treated once-only with the electrode device guided
      stereotactically through a burr hole using CT monitoring. The patient will be fully
      anesthetized during the treatment procedure. Patients are followed up for 6 months with
      regard to neurological function, Barthel Index, steroid use and adverse effects registration
      (CTCAE). Tumor response will be evaluated by Magnetic Resonance imaging (MRI).

      The first 6 patients will receive an intravenous dose of bleomycin 15.000 IE/m2 before
      electric pulses. The following patients will receive an additional intratumoral injection of
      bleomycin of increasing concentration. The electrical pulses will consist of a series of high
      voltage pulses of 0.1 millisecond duration.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to slow patient recruitment
  </why_stopped>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of the trial treatment. This is evaluated by adverse events registrations (CTCAE).</measure>
    <time_frame>From treatment to last follow up, planned 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the trial treatment. This is evaluated by target tumor response on Magnetic resonance imaging (MRI).</measure>
    <time_frame>Patients are evaluable 50 days after treatment</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">1</enrollment>
  <condition>Brain Metastases</condition>
  <condition>CNS Metastases</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The Electroporation System</intervention_name>
    <description>The Electroporation System comprises of 3 parts: 1.Switch Box, 2. Driver, 3. Brain Probe</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bleomycin</intervention_name>
    <description>Bleomycin dosage for i.v. use is 15.000 IU/m2, and is administered 10-30 minutes before the electric pulses. Bleomycin dosage for intratumoral use is either 2.000 IU, 4.000 IU, or 6.000 IU per 3 ml, and 20 % of the calculated tumor volume is injected.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt; 18 years.

          -  Performance status &lt; 2 (ECOG - Eastern Cooperative Oncology Group).

          -  Diagnosis of brain metastases originated from histological or cytological verified
             cancer of any histology.

          -  Patients should have received whole-brain radiation therapy (WBRT) with a time
             interval of at least 2 months from completion of WBRT until inclusion in this study.

          -  Patients must have been offered every available standard treatment.

          -  Brain metastases to be treated must have a diameter of at least 10 millimetres and no
             more than 27 millimetres.

          -  Brain metastases to be treated must be accessible for treatment.

          -  Estimated life expectancy must be more than 3 months.

          -  Patients must have adequate organ functions:

        Adequate bone marrow reserve: Leucocytes (WBC) &gt; 3.0 x 109/l, thrombocytes &gt; 75 x 109/l,
        hemoglobin &gt; 7 g/dl.

        Hepatic: Alkaline phosphate, ALAT or ASAT and bilirubin must not be increased more than 2
        times, pp &gt; 40, APTT in normal range. Medical correction is allowed, e.g. correction of low
        pp using vitamin K.

        Renal: if creatinin &gt; 150 micromolar do a GFR examination (Chrome-EDTA).

          -  Patients must not have a blood pressure (BP) over 180 mm Hg systolic and 110 mm Hg
             diastolic.

          -  Sexually active men and women of childbearing potential must use adequate birth
             control during this study and 6 month after the administration of bleomycin
             (contraceptive pills, intrauterine devices, injection of prolonged gestagen, subdermal
             implantation, hormonal vaginal devices, transdermal patches).

          -  Participating patients must be able to understand the patient information.

          -  Participating patients must have signed a written informed consent and power of
             attorney prior to inclusion in this study.

        Exclusion Criteria:

          -  Acute lung infection.

          -  Previous bleomycin treatment with more than 200.000 IU/m2.

          -  Previous allergic reaction to bleomycin.

          -  Allergy towards the sedation used.

          -  Pregnancy or breastfeeding. Pregnancy in fertile women is excluded by a measurement of
             HCG in a blood sample. Sterile or infertile women are excluded from the requirement to
             use anticonception. To be considered sterile or infertile, the patient must have
             undergone surgical sterilization (vasectomy/bilateral tubectomy, hysterectomy and
             bilateral ovariectomy) or be post-menopausal defined as the absence of menstruation.

          -  Treatment with G-CSF (Granulocyte Colony Stimulating Factor) or other cytokines.

          -  Lung diffusion capacity (DLCO) below normal. DLCO is to be performed in case of
             suspected (anamnestic or clinical) reduced lung function.

          -  Physician's assessment that meningeal carcinomatosis (leptomeningeal disease) is a
             likely cause of the patient's symptoms.

          -  Treatment with anticoagulants (marevan, marcumar, innohep).

          -  Allergic to nickel, chrome or cobalt.

          -  Participation in another clinical study with an experimental drug up to 4 weeks prior
             to inclusion.

          -  Illnesses, medical, social or physiological, that may affect the patient's ability to
             understand the patient information and participate in the follow-up.

          -  Other serious systemic illnesses (i.e. active infection, abnormal EKG) that the
             investigator finds may affect the patient's safety and/or ability to complete the
             study.

          -  Treatment with Immunosuppressant drugs such as methotrexate and cyclosporine during
             the study. Treatment with prednisolone is accepted during the study.

          -  Implanted pacemaker, defibrillators or hearth valve prosthetics.

          -  Implanted devices such as neurostimulators, eartransplants, insulinpump, metallic
             tracheostomy.

          -  Catheters with metal such as Port รก cath, Swan Ganz, P-dialysis cath.,
             ventriculoatrial and -peritoneal shunts, bladder cath. with thermo-measurement.

          -  Metallic clips/prosthetics/magnets from surgery such as neuro- or abdominal clips,
             tooth- or other prosthetics.

          -  Disorganised metallic material such as metal fragments in the eyes, shrapnel, gun shot
             injuries.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie Gehl, MD, DMSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology, Herlev Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Linnert M, Gehl J. Bleomycin treatment of brain tumors: an evaluation. Anticancer Drugs. 2009 Mar;20(3):157-64. doi: 10.1097/CAD.0b013e328325465e. Review.</citation>
    <PMID>19396014</PMID>
  </reference>
  <reference>
    <citation>Gothelf A, Mir LM, Gehl J. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev. 2003 Oct;29(5):371-87. Review.</citation>
    <PMID>12972356</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2011</study_first_submitted>
  <study_first_submitted_qc>March 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2011</study_first_posted>
  <last_update_submitted>July 30, 2013</last_update_submitted>
  <last_update_submitted_qc>July 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain Metastases, CNS Metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bleomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

